Cargando…
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
Wide-spread cancer-related immunosuppression often curtails immune-mediated antitumoral responses. Immune-checkpoint inhibitors (ICIs) have become a state-of-the-art treatment modality for mismatch repair-deficient (dMMR) tumors. Still, the impact of ICI-treatment on bone marrow perturbations is lar...
Autores principales: | Krone, Paula, Wolff, Annabell, Teichmann, Julia, Maennicke, Johanna, Henne, Julia, Engster, Leonie, Salewski, Inken, Bergmann, Wendy, Junghanss, Christian, Maletzki, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312035/ https://www.ncbi.nlm.nih.gov/pubmed/37396958 http://dx.doi.org/10.1080/2162402X.2023.2230669 |
Ejemplares similares
-
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022) -
Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
por: Salewski, Inken, et al.
Publicado: (2021) -
Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021) -
In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters
por: Salewski, Inken, et al.
Publicado: (2020) -
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
por: Riess, Christin, et al.
Publicado: (2020)